Renaissance Technologies’s Filana Therapeutics FLNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $552K | Buy |
+326,759
| New | +$673K | ﹤0.01% | 2561 |
|
|
2024
Q4 | – | Sell |
-81,100
| Closed | -$2.39M | – | 3866 |
|
|
2024
Q3 | $2.39M | Buy |
+81,100
| New | +$1.87M | ﹤0.01% | 1896 |
|
|
2020
Q4 | – | Sell |
-112,300
| Closed | -$1.29M | – | 3672 |
|
|
2020
Q3 | $1.29M | Buy |
+112,300
| New | +$506K | ﹤0.01% | 2372 |
|
|
2020
Q2 | – | Sell |
-653,759
| Closed | -$2.69M | – | 3718 |
|
|
2020
Q1 | $2.69M | Sell |
653,759
-362,000
| -36% | -$2.4M | ﹤0.01% | 1899 |
|
|
2019
Q4 | $5.28M | Buy |
1,015,759
+163,801
| +19% | +$283K | ﹤0.01% | 1817 |
|
|
2019
Q3 | $1.02M | Buy |
851,958
+169,166
| +25% | +$217K | ﹤0.01% | 2585 |
|
|
2019
Q2 | $826K | Buy |
682,792
+98,900
| +17% | +$112K | ﹤0.01% | 2781 |
|
|
2019
Q1 | $753K | Buy |
583,892
+50,800
| +10% | +$58.3K | ﹤0.01% | 2791 |
|
|
2018
Q4 | $453K | Buy |
533,092
+272,009
| +104% | +$313K | ﹤0.01% | 2902 |
|
|
2018
Q3 | $264K | Buy |
261,083
+233,121
| +834% | +$354K | ﹤0.01% | 3055 |
|
|
2018
Q2 | $58K | Buy |
27,962
+2,400
| +9% | +$20.6K | ﹤0.01% | 3182 |
|
|
2018
Q1 | $181K | Sell |
25,562
-36,359
| -59% | -$245K | ﹤0.01% | 3197 |
|
|
2017
Q4 | $248K | Sell |
61,921
-16,600
| -21% | -$67K | ﹤0.01% | 3077 |
|
|
2017
Q3 | $320K | Buy |
78,521
+13,900
| +22% | +$49.7K | ﹤0.01% | 2890 |
|
|
2017
Q2 | $268K | Sell |
64,621
-27,206
| -30% | -$128K | ﹤0.01% | 2929 |
|
|
2017
Q1 | $574K | Sell |
91,827
-27,628
| -23% | -$125K | ﹤0.01% | 2733 |
|
|
2016
Q4 | $477K | Sell |
119,455
-10,572
| -8% | -$49K | ﹤0.01% | 2783 |
|
|
2016
Q3 | $910K | Buy |
130,027
+15,772
| +14% | +$261K | ﹤0.01% | 2613 |
|
|
2016
Q2 | $1.75M | Buy |
114,255
+10,400
| +10% | +$165K | ﹤0.01% | 2271 |
|
|
2016
Q1 | $1.62M | Buy |
103,855
+7,743
| +8% | +$100K | ﹤0.01% | 2350 |
|
|
2015
Q4 | $1.18M | Buy |
96,112
+10,914
| +13% | +$144K | ﹤0.01% | 2386 |
|
|
2015
Q3 | $1.09M | Buy |
85,198
+10,957
| +15% | +$138K | ﹤0.01% | 2338 |
|
|
2015
Q2 | $899K | Buy |
74,241
+25,857
| +53% | +$354K | ﹤0.01% | 2498 |
|
|
2015
Q1 | $640K | Buy |
48,384
+4,900
| +11% | +$66.1K | ﹤0.01% | 2511 |
|
|
2014
Q4 | $618K | Sell |
43,484
-6,528
| -13% | -$113K | ﹤0.01% | 2360 |
|
|
2014
Q3 | $1.37M | Buy |
50,012
+2,285
| +5% | +$69.4K | ﹤0.01% | 1868 |
|
|
2014
Q2 | $1.92M | Sell |
47,727
-9,628
| -17% | -$356K | ﹤0.01% | 1752 |
|
|
2014
Q1 | $2.21M | Sell |
57,355
-22,014
| -28% | -$777K | 0.01% | 1717 |
|
|
2013
Q4 | $2.7M | Sell |
79,369
-59,871
| -43% | -$1.59M | 0.01% | 1582 |
|
|
2013
Q3 | $2.65M | Sell |
139,240
-1,042
| -0.7% | -$18.2K | 0.01% | 1521 |
|
|
2013
Q2 | $2.17M | Buy |
+140,282
| New | +$2.97M | 0.01% | 1535 |
|
Other funds holding FLNA
VCM
GC
Renaissance Technologies's FLNA Position: Q1 2026 in Review
Renaissance Technologies opened a new position in Filana Therapeutics (FLNA) in Q1 2026: 326,759 shares worth $552K. The stake represents ﹤0.01% of the portfolio and ranks #2561 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in FLNA as recently as Q3 2024.
Renaissance Technologies first reported a position in FLNA in Q2 2013 and has held it in 31 quarters since. The position peaked at $5.28M in Q4 2019. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.
- Renaissance Technologies held 326,759 shares of Filana Therapeutics worth $552K as of Q1 2026.
- Filana Therapeutics was a new Renaissance Technologies position in Q1 2026.
- Filana Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2561 holding.
- Renaissance Technologies first reported a position in Filana Therapeutics in Q2 2013 and has held it in 31 quarters since.
- Renaissance Technologies's Filana Therapeutics position peaked at $5.28M in Q4 2019.
- 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.